Only drugs categorized as a basic refund type are possible when a pharmaceutical company wishes to terminate the Risk Sharing Agreement (RSA) early. However, pharmaceuticals on the cost-effectiveness evaluation waiver track, demonstrating cost-effectiveness, can be submitted for negotiation through the renewal of the agreement.

The National Health Insurance Service (NHIS) has finalized the 'Guidelines for Drug Price Negotiations and Detailed matters.' On the afternoon of December 19, the NHIS held a briefing session at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA) to explain the revisions made to the 'Guidelines for Drug Price Negotiations' and the 'Guidelines for Dr